Britain’s AI reckoning: when surveillance becomes a mental health crisis

The NHS’s creepy experiment: when care becomes surveillance

The Oxevision system is now installed in 40% of NHS mental health trusts. It watches patients in their bedrooms—ostensibly to prevent self-harm. But the Information Commissioner’s Office (ICO) has just opened an inquiry, and patients are calling it “spying.” One mother blames it for her daughter’s suicide, claiming the cameras amplified her paranoia. The NHS insists it’s about safety. The reality? A collision between innovation and dignity, where the most vulnerable pay the price.

This isn’t just about technology. It’s about power. The NHS, already stretched to breaking point, is outsourcing care to algorithms. But who polices the police? The ICO’s investigation is a start, but it’s reactive, not preventative. Where was the ethical review before 40% of trusts rolled out bedroom cameras? Where was the patient consent?

The answer is nowhere. Because in Britain’s innovation arms race, human rights are an afterthought.

Microplastics in pet food: the invisible scandal no one’s talking about

A new study finds microplastics in over 75% of pet food. Some brands are worse than others. The implications? Unknown. But if we’re feeding our dogs and cats plastic, what’s it doing to us?

The pet food industry is a £3.5bn market in the UK, and it’s unregulated when it comes to microplastics. No labels. No warnings. No recalls. Just silent contamination, because the government hasn’t bothered to set limits. Meanwhile, supermarkets stock the same brands that tested positive, and consumers are none the wiser.

This isn’t just an environmental issue. It’s a class issue. The cheapest pet foods are the most contaminated. The people who can least afford vet bills are the ones feeding their animals plastic. And the government? It’s too busy chasing AI headlines to notice.

Midjourney’s medical spa: when Silicon Valley’s hype becomes a health hazard

Midjourney, the AI image generator, is pivoting to “medical imaging.” Its new venture, Midjourney Medical, promises MRI-like scans using ultrasound sensors in a “golden light” spa. The pitch? “Step into the future of wellness.”

The reality? A gimmick with no regulatory approval. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has no record of Midjourney’s tech being certified for medical use. Yet the company is already selling scans to the public, framing them as a luxury experience rather than a diagnostic tool.

This is how Silicon Valley operates: move fast, break things, and let someone else clean up the mess. In this case, the “things” are human bodies. The “mess”? Misdiagnoses, false reassurance, and a healthcare system left to pick up the pieces.

The NHS is drowning in waiting lists. Midjourney is selling spa days disguised as medical innovation. And the government? It’s too busy debating AI ethics in Whitehall to notice the grift happening in plain sight.

The AI brain drain: OpenAI’s revolving door and the cost of “disruption”

Barret Zoph, OpenAI’s head of enterprise AI, is out—again. This time after just five months. His return in January was hailed as a coup. His departure? A footnote.

OpenAI’s leadership churn is becoming a pattern. Executives arrive with fanfare, leave in silence. The company’s IPO looms, and its focus has narrowed to “revenue drivers” like enterprise AI. But what happens when the people building the future keep walking out the door?

The answer is simple: innovation stalls. Morale collapses. And the public is left with half-baked products sold as breakthroughs. OpenAI’s pivot to “enterprise” isn’t just a business strategy—it’s an admission of failure. The company promised artificial general intelligence. What it’s delivering? Expensive PowerPoint slides for corporations.

Britain’s AI strategy is built on partnerships with firms like OpenAI. But if the talent keeps fleeing, what’s left? A hollowed-out industry, propped up by hype and government grants.

What Britain must learn

The common thread here is accountability. The NHS deploys surveillance tech without consent. Pet food giants poison animals with plastic. Midjourney sells medical scans like spa treatments. OpenAI treats talent like disposable assets.

Innovation isn’t the problem. The problem is innovation without guardrails. Britain’s tech sector is racing ahead, but its regulators are stuck in the past. The ICO’s inquiry into Oxevision is a step. But it’s not enough.

The question isn’t whether AI can save lives. It’s whether Britain’s institutions can save us from AI. So far, the answer is no.